Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

Lignende værker

• Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
  af: Gerds, AT, et al.
  Udgivet: (2020)
• Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
  af: Mesa, R, et al.
  Udgivet: (2017)
• RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
  af: O'Sullivan, JM, et al.
  Udgivet: (2023)
• Practical management of patients with myelofibrosis receiving ruxolitinib.
  af: Harrison, C, et al.
  Udgivet: (2013)
• MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
  af: Verstovsek, S, et al.
  Udgivet: (2021)